Review of NICE Technology Appraisal Guidance No.185; Trabectedin for the treatment of advanced metastatic soft tissue sarcoma

The planned date for review of the above guidance is February 2013.

This is the date at which the Institute decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a full review appraisal.

Since the publication of TA185, no additional trial-based evidence on the use of trabectedin in advanced soft tissue sarcoma has been produced.  As there is no new evidence available that would lead to a change in the recommendations, it is proposed that the original guidance become static.

Topics on the static list may be transferred back to the active list for further appraisal if new evidence becomes available that is likely to have a material effect on the last guidance issued.

In order to be completely confident that this is appropriate, we are asking all relevant consultees and commentators, to inform us of any evidence which would suggest that a review would be beneficial.  Please see appendix A for a full list of the organisations we have contacted. 

February 2013